Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vildatin Plus is a fixed-dose combination generic drug containing the dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin and the biguanide antihyperglycemic agent metformin hydrochloride. Marketed by Alfa Pharma and manufactured by Celogen Pharma, it is indicated for the treatment of type 2 diabetes mellitus to improve glycemic control in adults. Vildagliptin works by inhibiting the DPP-4 enzyme, which prevents the degradation of incretin hormones like GLP-1 and GIP, thereby enhancing glucose-dependent insulin secretion and suppressing glucagon release. Metformin hydrochloride works primarily by decreasing hepatic glucose production, reducing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. Together, these complementary mechanisms provide superior glycemic control compared to either monotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metformin + vildagliptin (Alfa Pharma).